Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of nivolumab ± BMS-986205 with or without intravesical BCG in BCG-unresponsive high-risk non-muscle invasive bladder cancer
2017-003581-27Phase 2Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- May 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nivolumab, linrodostat and bcg vaccine in non-muscle-invasive bladder cancer (NMIBC) (4 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Complete response rate in carcinoma in situ participants and Duration of complete response in carcinoma in situ participants. Started May 2018; status: terminated.
02
Drugs
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on 2017-003581-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003581-27.